Congrats to Ted on his first, first-author paper describing some new IP-FCM assays that he’s been working non-stop on for the past two months. We detect anti-SARS-CoV-2 antibodies in almost all recovered patients, and we detect inhibition of SARS-2 spike protein binding to its receptor, ACE2. Our cell-free inhibition assay, based on IP-FCM, could be useful to quantify immunity in recovered patients or vaccine trials. Big thanks to our collaborators at SCRI, Drs. Whitney Harrington, Noah Sather and Lisa Frenkel. We’re very proud to be a small part of the global, collaborative effort to fight COVID-19.
https://www.medrxiv.org/content/10.1101/2020.06.09.20127050v1